80 related articles for article (PubMed ID: 6262159)
1. Cell substrate and risk in killed poliomyelitis vaccine.
Horodniceanu F; Crainic R; Barme M
Dev Biol Stand; 1981; 47():35-9. PubMed ID: 6262159
[TBL] [Abstract][Full Text] [Related]
2. Presence and quantification of cell substrate DNA in inactivated poliovirus vaccine.
Crainic R; Horodniceanu F; Barme M
Dev Biol Stand; 1980; 46():275-9. PubMed ID: 6245003
[TBL] [Abstract][Full Text] [Related]
3. Cell substrate for killed poliovaccine production.
Beale AJ
Dev Biol Stand; 1981; 47():19-23. PubMed ID: 6262147
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of cell DNA in the evaluation of heteroploid cells as substrate for the preparation of killed viral vaccines.
Crainic R; Horodniceanu F; Barme M
Intervirology; 1980; 14(5-6):300-9. PubMed ID: 6265401
[TBL] [Abstract][Full Text] [Related]
5. Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine.
Tatalick LM; Gerard CJ; Takeya R; Price DN; Thorne BA; Wyatt LM; Anklesaria P
Vaccine; 2005 Apr; 23(20):2628-38. PubMed ID: 15780446
[TBL] [Abstract][Full Text] [Related]
6. Thousand litre scale microcarrier culture of Vero cells for killed polio virus vaccine. Promising results.
Montagnon B; Vincent-Falquet JC; Fanget B
Dev Biol Stand; 1983; 55():37-42. PubMed ID: 6677539
[TBL] [Abstract][Full Text] [Related]
7. [Use of diploid cell lines as a multiplication substrate for viral vaccine production].
Welke G
Z Gesamte Hyg; 1980; 26(5):365-72. PubMed ID: 7008390
[No Abstract] [Full Text] [Related]
8. Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines.
Laassri M; Lottenbach K; Belshe R; Rennels M; Plotkin S; Chumakov K
J Infect Dis; 2006 May; 193(10):1344-9. PubMed ID: 16619180
[TBL] [Abstract][Full Text] [Related]
9. Decision analysis in planning for a polio outbreak in the United States.
Jenkins PC; Modlin JF
Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
[TBL] [Abstract][Full Text] [Related]
10. Killed poliovaccine: an evaluation of safety testing.
van Steenis G; van Wezel AL
Dev Biol Stand; 1981; 47():143-50. PubMed ID: 6262145
[TBL] [Abstract][Full Text] [Related]
11. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains.
Minor PD; Dunn G; Ramsay ME; Brown D
J Med Virol; 2005 Jan; 75(1):153-60. PubMed ID: 15543587
[TBL] [Abstract][Full Text] [Related]
12. The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine.
Montagnon BJ; Fanget B; Nicolas AJ
Dev Biol Stand; 1981; 47():55-64. PubMed ID: 6785126
[TBL] [Abstract][Full Text] [Related]
13. Quantitative determination of the infectivity of the proviral DNA of a retrovirus in vitro: Evaluation of methods for DNA inactivation.
Sheng-Fowler L; Lewis AM; Peden K
Biologicals; 2009 Aug; 37(4):259-69. PubMed ID: 19457682
[TBL] [Abstract][Full Text] [Related]
14. A retrovirus from human leukemia cell lines: its isolation, characterization, and implication in human adult T-cell leukemia (ATL).
Yoshida M; Miyoshi I; Hinuma Y
Princess Takamatsu Symp; 1982; 12():285-94. PubMed ID: 6984702
[TBL] [Abstract][Full Text] [Related]
15. Viral vaccines and residual cellular DNA.
Horaud F
Biologicals; 1995 Sep; 23(3):225-8. PubMed ID: 8527122
[TBL] [Abstract][Full Text] [Related]
16. Detection and elimination of cellular nucleic acids in biologicals produced on continuous cell lines.
van Wezel AL; van der Marel P; van Beveren CP; Verma I; Salk PL; Salk J
Dev Biol Stand; 1981; 50():59-69. PubMed ID: 6281112
[TBL] [Abstract][Full Text] [Related]
17. Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis.
Salk J; van Wezel AL; Stoeckel P; van Steenis G; Schlumberger M; Meyran M; Rey JL; Lapinleimu K; Böttiger M; Cohen H
Dev Biol Stand; 1981; 47():181-98. PubMed ID: 7194827
[TBL] [Abstract][Full Text] [Related]
18. Present state and developments in the production of inactivated poliomyelitis vaccine.
van Wezel AL
Dev Biol Stand; 1981; 47():7-13. PubMed ID: 6262162
[TBL] [Abstract][Full Text] [Related]
19. A modified single-tube one-step product-enhanced reverse transcriptase (mSTOS-PERT) assay with heparin as DNA polymerase inhibitor for specific detection of RTase activity.
Fan XY; Lü GZ; Wu LN; Chen JH; Xu WQ; Zhao CN; Guo SQ
J Clin Virol; 2006 Dec; 37(4):305-12. PubMed ID: 16971176
[TBL] [Abstract][Full Text] [Related]
20. Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen.
Salk J; Stoeckel P; van Wezel AL; Lapinleimu K; van Steenis G
Ann Clin Res; 1982 Dec; 14(5-6):204-12. PubMed ID: 7171229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
